|
1
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thun MJ, Namboodiri MM and Heath CW Jr:
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med.
325:1593–1596. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Logan RF, Little J, Hawtin PG and
Hardcastle JD: Effect of aspirin and non-steroidal
anti-inflammatory drugs on colorectal adenomas: case-control study
of subjects participating in the Nottingham faecal occult blood
screening programme. BMJ. 307:285–289. 1993. View Article : Google Scholar
|
|
4
|
Baron JA, Cole BF, Sandler RS, et al: A
randomized trial of aspirin to prevent colorectal adenomas. N Engl
J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Din FV, Theodoratou E, Farrington SM, et
al: Effect of aspirin and NSAIDs on risk and survival from
colorectal cancer. Gut. 59:1670–1679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
La Vecchia C, Negri E, Franceschi S, et
al: Aspirin and colorectal cancer. Br J Cancer. 76:675–677.
1997.
|
|
7
|
Corpet DE and Pierre F: Point: from animal
models to prevention of colon cancer. Systematic review of
chemoprevention in min mice and choice of the model system. Cancer
Epidemiol Biomarkers Prev. 12:391–400. 2003.PubMed/NCBI
|
|
8
|
Liu Y, Ju J, Xiao H, et al: Effects of
combination of calcium and aspirin on azoxymethane-induced aberrant
crypt foci formation in the colons of mice and rats. Nutr Cancer.
60:660–665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bousserouel S, Gosse F, Bouhadjar M, Soler
L, Marescaux J and Raul F: Long-term administration of aspirin
inhibits tumour formation and triggers anti-neoplastic molecular
changes in a pre-clinical model of colon carcinogenesis. Oncol Rep.
23:511–517. 2010.
|
|
10
|
Sansom OJ, Stark LA, Dunlop MG and Clarke
AR: Suppression of intestinal and mammary neoplasia by lifetime
administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(−/−)
mice. Cancer Res. 61:7060–7064. 2001.PubMed/NCBI
|
|
11
|
Lal G, Ash C, Hay K, et al: Suppression of
intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple
intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor
and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res.
61:6131–6136. 2001.PubMed/NCBI
|
|
12
|
Rothwell PM, Fowkes FG, Belch JF, Ogawa H,
Warlow CP and Meade TW: Effect of daily aspirin on long-term risk
of death due to cancer: analysis of individual patient data from
randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burn J, Gerdes AM, Macrae F, et al:
Long-term effect of aspirin on cancer risk in carriers of
hereditary colorectal cancer: an analysis from the CAPP2 randomised
controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar
|
|
14
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: a study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan AT, Ogino S and Fuchs CS: Aspirin use
and survival after diagnosis of colorectal cancer. JAMA.
302:649–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Laine L: The gastrointestinal effects of
nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis
Rheum. 32:25–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gasche C, Goel A, Natarajan L and Boland
CR: Mesalazine improves replication fidelity in cultured colorectal
cells. Cancer Res. 65:3993–3997. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campregher C, Honeder C, Chung H,
Carethers JM and Gasche C: Mesalazine reduces mutations in
transforming growth factor β receptor II and activin type II
receptor by improvement of replication fidelity in mononucleotide
repeats. Clin Cancer Res. 16:1950–1956. 2010.PubMed/NCBI
|
|
19
|
McIlhatton MA, Tyler J, Burkholder S, et
al: Nitric oxide-donating aspirin derivatives suppress
microsatellite instability in mismatch repair-deficient and
hereditary nonpolyposis colorectal cancer cells. Cancer Res.
67:10966–10975. 2007. View Article : Google Scholar
|
|
20
|
Tesei A, Zoli W, Fabbri F, et al: NCX
4040, an NO-donating acetylsalicylic acid derivative: efficacy and
mechanisms of action in cancer cells. Nitric Oxide. 19:225–236.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Selvendiran K, Bratasz A, Tong L, Ignarro
LJ and Kuppusamy P: NCX-4016, a nitro-derivative of aspirin,
inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in
cisplatin-resistant human ovarian cancer cells and xenografts. Cell
Cycle. 7:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao W, Mackenzie GG, Murray OT, Zhang Z
and Rigas B: Phosphoaspirin (MDC-43), a novel benzyl ester of
aspirin, inhibits the growth of human cancer cell lines more
potently than aspirin: a redox-dependent effect. Carcinogenesis.
30:512–519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang D and DuBois RN: Pro-inflammatory
prostaglandins and progression of colorectal cancer. Cancer Lett.
267:197–203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sheng H, Shao J, Morrow JD, Beauchamp RD
and DuBois RN: Modulation of apoptosis and Bcl-2 expression by
prostaglandin E2 in human colon cancer cells. Cancer Res.
58:362–366. 1998.PubMed/NCBI
|
|
25
|
Harris RE, Beebe-Donk J and Alshafie GA:
Similar reductions in the risk of human colon cancer by selective
and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer.
8:2372008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA
and Morgan G: Aspirin, salicylates, and cancer. Lancet.
373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dibra HK, Perry CJ and Nicholl ID:
Non-steroidal anti-inflammatory drugs, DNA repair and cancer. DNA
Repair and Human Health. Vengrova S: InTech; pp. 743–776. 2011,
http://cdn.intechopen.com/pdfs-wm/22182.pdf.
|
|
28
|
Kopp E and Ghosh S: Inhibition of NF-kappa
B by sodium salicylate and aspirin. Science. 265:956–959. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thoms HC, Dunlop MG and Stark LA:
p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4
stimulates nucleolar translocation of RelA and apoptosis in
colorectal cancer cells. Cancer Res. 67:1660–1669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu HG, Huang JA, Yang YN, et al: The
effects of acetylsalicylic acid on proliferation, apoptosis, and
invasion of cyclooxygenase-2 negative colon cancer cells. Eur J
Clin Invest. 32:838–846. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luciani MG, Campregher C and Gasche C:
Aspirin blocks proliferation in colon cells by inducing a G1 arrest
and apoptosis through activation of the checkpoint kinase ATM.
Carcinogenesis. 28:2207–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shureiqi I, Chen D, Lotan R, et al:
15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory
drug-induced apoptosis independently of cyclooxygenase-2 in colon
cancer cells. Cancer Res. 60:6846–6850. 2000.PubMed/NCBI
|
|
33
|
Goel A, Chang DK, Ricciardiello L, Gasche
C and Boland CR: A novel mechanism for aspirin-mediated growth
inhibition of human colon cancer cells. Clin Cancer Res. 9:383–390.
2003.PubMed/NCBI
|
|
34
|
Pangburn HA, Kraus H, Ahnen DJ and Rice
PL: Sulindac metabolites inhibit epidermal growth factor receptor
activation and expression. J Carcinog. 4:162005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pangburn HA, Ahnen DJ and Rice PL:
Sulindac metabolites induce proteosomal and lysosomal degradation
of the epidermal growth factor receptor. Cancer Prev Res.
3:560–572. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruschoff J, Wallinger S, Dietmaier W, et
al: Aspirin suppresses the mutator phenotype associated with
hereditary nonpolyposis colorectal cancer by genetic selection.
Proc Natl Acad Sci USA. 95:11301–11306. 1998. View Article : Google Scholar
|
|
37
|
Deb J, Dibra H, Shan S, et al: Activity of
aspirin analogues and vanillin in a human colorectal cancer cell
line. Oncol Rep. 26:557–565. 2011.PubMed/NCBI
|
|
38
|
Hussey HJ and Tisdale MJ: Effect of
polyunsaturated fatty acids on the growth of murine colon
adenocarcinomas in vitro and in vivo. Br J Cancer. 70:6–10. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: assessment of chemosensitivity testing. Cancer
Res. 47:936–942. 1987.PubMed/NCBI
|
|
41
|
Stark LA and Dunlop MG: Nucleolar
sequestration of RelA (p65) regulates NF-κB-driven transcription
and apoptosis. Mol Cell Biol. 25:5985–6004. 2005.PubMed/NCBI
|
|
42
|
Stark LA, Din FV, Zwacka RM and Dunlop MG:
Aspirin-induced activation of the NF-κB signaling pathway: a novel
mechanism for aspirin-mediated apoptosis in colon cancer cells.
FASEB J. 15:1273–1275. 2001.
|
|
43
|
Loveridge CJ, MacDonald AD, Thoms HC,
Dunlop MG and Stark LA: The proapoptotic effects of sulindac,
sulindac sulfone and indomethacin are mediated by nucleolar
translocation of the RelA(p65) subunit of NF-κB. Oncogene.
27:2648–2655. 2008.PubMed/NCBI
|
|
44
|
Campbell KJ, Rocha S and Perkins ND:
Active repression of antiapoptotic gene expression by RelA(p65)
NF-κB. Mol Cell. 13:853–865. 2004.PubMed/NCBI
|
|
45
|
Walder JA, Zaugg RH, Walder RY, Steele JM
and Klotz IM: Diaspirins that cross-link beta chains of hemoglobin:
bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl)
fumarate. Biochemistry. 18:4265–4270. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alfonso LF, Srivenugopal KS and Bhat GJ:
Does aspirin acetylate multiple cellular proteins? (Review). Mol
Med Rep. 2:533–537. 2009.PubMed/NCBI
|
|
47
|
Schwenger P, Alpert D, Skolnik EY and
Vilcek J: Cell typespecific activation of c-Jun N-terminal kinase
by salicylates. J Cell Physiol. 179:109–114. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kojima M, Morisaki T, Sasaki N, et al:
Increased nuclear factor-kB activation in human colorectal
carcinoma and its correlation with tumor progression. Anticancer
Res. 24:675–681. 2004.PubMed/NCBI
|
|
49
|
Greenspan EJ, Madigan JP, Boardman LA and
Rosenberg DW: Ibuprofen inhibits activation of nuclear β-catenin in
human colon adenomas and induces the phosphorylation of GSK-3β.
Cancer Prev Res. 4:161–171. 2011.
|
|
50
|
Thoms HC, Loveridge CJ, Simpson J, et al:
Nucleolar targeting of RelA(p65) is regulated by COMMD1-dependent
ubiquitination. Cancer Res. 70:139–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Meltzer PC, Blundell P, Yong YF, et al:
2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen
inhibitors of monoamine transporters. J Med Chem. 43:2982–2991.
2000.PubMed/NCBI
|
